Notice Number: NOT-AI-19-016
Key Dates
Release Date: December 11, 2018
Issued by
National Institute of Allergy and Infectious Diseases (NIAID)
Purpose
The purpose of this Notice is to update the Objective for PAR-18-319 "HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed)" to inform the applicant community of an additional area of interest by NIAID.
Part 2.Section I. Funding Opportunity Description
Objective
Current language:
The HIV Vaccine Research and Design (HIVRAD) program is designed to fund projects that further address hypotheses crucial to the design of an efficacious HIV/AIDS prophylactic vaccine. Applications for five years of support should include plans that have advanced past the exploratory stage and include preliminary data. Applications aimed at developing or optimizing a specific vaccine platform should lay out a research pathway with clear decision points. Extensive modeling of vaccine concepts in non-human primates may be included.
Applications may address, but need not be limited to:
Note:The following types of studies will not be supported under this FOA:
Revised language:
The HIV Vaccine Research and Design (HIVRAD) program is designed to fund projects that further address hypotheses crucial to the design of an efficacious HIV/AIDS prophylactic vaccine. Applications for five years of support should include plans that have advanced past the exploratory stage and include preliminary data. Applications aimed at developing or optimizing a specific vaccine platform should lay out a research pathway with clear decision points. Extensive modeling of vaccine concepts in non-human primates may be included.
Applications may address, but need not be limited to:
Note:The following types of studies will not be supported under this FOA:
Inquiries
Please direct all inquiries to:
Alan Schultz, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-292-6169
Email:[email protected]